GlassScriptPhysician profile
John Francis Sullivan
NPI 1801153614
$3,840.11
in general payments reported to CMS, 2019-2025
21 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $295 · 2021: $98.53 · 2022: $451 · 2023: $460 · 2024: $941 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.87 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,354.39 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $526.00 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $476.72 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $462.56 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.35 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Ardelyx, INC. | $198.42 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $63.99 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $58.74 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $34.42 | 2024 | |
| Madrigal Pharmaceuticals | $33.74 | 2025 | Rezdiffra |
| Sandoz INC. | $31.60 | 2023-2024 | Hyrimoz |
| Genzyme Corporation | $26.88 | 2024 | |
| Allergan, INC. | $24.09 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.66 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $17.45 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $16.69 | 2022 | |
| Novo Nordisk INC | $15.87 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $14.69 | 2022 | |
| Shire North American Group INC | $13.23 | 2019 | |
| Shionogi INC | $12.30 | 2019 | |
| Merck Sharp & Dohme LLC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.